Kim, Jin Sun,Kim, Dae Jin,Lee, Sang Hyun,Jung, Sung Youb,Kwon, Se Chang
申请号：
AU2018200138
公开号：
AU2018200138B2
申请日:
2018.01.08
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
#$%^&*AU2018200138B220190912.pdf#####ABSTRACT The present invention relates to a composition for preventing or treating diabetes, disbesity or diabetic complications, comprising an oxyntomodulin analog as an active ingredient. The invention also relates to a method for treating diabetes, diabesity or diabetic complications, comprising administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog has a high ability to activate the GLP-1 receptor and the glucagon receptor, compared to native oxyntomodulin. The oxyntomodulin analog induces the expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in body weight and diet intake to improve insulin sensitivity and allow blood glucose levels, which are not controlled due to insulin resistance, to be maintained at normallevels. Thus, the oxyntomodulin analog can be effectively used to prevent or treat of diabetes and related diseases. Vehicle Victoza 6rnoukg(Dabetes) m Victoza 100nmokg(Obesty) 0 Seq ID No.23-Fo conjugate Snmol/kg W SeqD No.25-Fc conjugateSrimollkg 20000E M2 QWO 2014/073845 PCT/KR2013/009990 [Fig. 4] Vehicle Victoza 6rmiollkg(Diabetes) Victoza 100nmol/kg(Obesity) Seq ID No.23-Fc conjugate 15nmol/kg Seq ID No.25-Fc conjugate 6nmol/kg >；200001 15000 i E ~10000CI
